BridgeBio Q2 revenue triples to $222M; CEO adopts 10b5-1 plan; $934M preferred financing closes post-quarter
BBIO sits 88% above its 52-week low of $45.395.
Summary
BridgeBio's Q2 2026 revenue surged to $222M on Attruby sales, while the company disclosed a new CEO trading plan, a $500M buyback, and a post-quarter $934M preferred stock financing — reshaping its capital structure ahead of key regulatory catalysts.
Key Events · Earnings and Guidance · BBIO
-
Attruby Revenue Triples
Net product revenue reached $222.4 million in Q2 2026, up from $71.5 million a year ago, driven by continued U.S. commercial expansion.
-
CEO Adopts 10b5-1 Trading Plan
CEO Neil Kumar adopted a Rule 10b5-1 plan on May 13, 2026, covering potential sales of up to 120,000 shares plus shares from RSU/PSU vesting, with sales not permitted before mid-August 2026.
-
$500M Share Buyback Program
The board authorized a $500 million repurchase program in May 2026; through June 30, 1.9 million shares were bought back for $127.5 million at an average price of $66.96.
-
Convertible Notes Now Convertible
The $550 million 2027 Notes and $575 million 2031 Notes became convertible from July 1 through September 30, 2026, adding potential near-term dilution pressure.
Analysis · BBIO · Life Sciences
Attruby's commercial momentum is the headline, with net product revenue reaching $222.4 million in Q2 2026 — more than triple the year-ago quarter. While the company remains unprofitable, the net loss narrowed, and it ended June with $720 million in cash and equivalents. More importantly, the capital structure is in flux: the 2027 and 2031 notes are now convertible, and just after the quarter closed, BridgeBio raised $933.9 million in convertible preferred stock from Sixth Street and KKR. That deal, alongside a new $500 million buyback program and a CEO 10b5-1 trading plan, signals a company aggressively managing its balance sheet and dilution ahead of multiple upcoming PDUFA dates.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BBIO was trading at $85.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.6B. The 52-week trading range was $45.40 to $93.42. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.